| 臺大學術典藏 |
2020-05-26T09:26:38Z |
Osimertinib in pretreated T790M-positive advanced non-small-cell lung cancer: AURA study phase II extension component
|
J?nne P.A.;Ghiorghiu S;Cantarini M;Mann H;Lin C.-C;Hirashima T;Gold K;Novello S;Yoh K;Haggstrom D;Blackhall F;Felip E;Planchard D;Kim J.-H;Kim S.-W;Su W.-C;Sequist L.V;Ramalingam S.S;Kim D.-W;Ahn M.-J;Chih-Hsin Yang; CHIH-HSIN YANG; Ahn M.-J; Kim D.-W; Ramalingam S.S; Sequist L.V; Su W.-C; Kim S.-W; Kim J.-H; Planchard D; Felip E; Blackhall F; Haggstrom D; Yoh K; Novello S; Gold K; Hirashima T; Lin C.-C; Mann H; Cantarini M; Ghiorghiu S; Jänne P.A. |
| 臺大學術典藏 |
2020-05-26T09:26:37Z |
Plasma ctDNA Analysis for Detection of the EGFR?T790M Mutation in Patients with Advanced Non?�Small?Cell Lung Cancer
|
Goss G.D.;Mitsudomi T;J?nne P.A;Cantarini M;Hodge R;Weston S;Patel S;Yu K;Ramalingam S.S;Chih-Hsin Yang;Jenkins S; Jenkins S; CHIH-HSIN YANG; Ramalingam S.S; Yu K; Patel S; Weston S; Hodge R; Cantarini M; Jänne P.A; Mitsudomi T; Goss G.D. |
| 臺大學術典藏 |
2020-05-26T09:26:37Z |
Plasma ctDNA Analysis for Detection of the EGFR?T790M Mutation in Patients with Advanced Non?�Small?Cell Lung Cancer
|
Goss G.D.;Mitsudomi T;J?nne P.A;Cantarini M;Hodge R;Weston S;Patel S;Yu K;Ramalingam S.S;Chih-Hsin Yang;Jenkins S; Jenkins S; CHIH-HSIN YANG; Ramalingam S.S; Yu K; Patel S; Weston S; Hodge R; Cantarini M; Jänne P.A; Mitsudomi T; Goss G.D. |
| 臺大學術典藏 |
2020-05-26T09:26:37Z |
EGFR Mutation Analysis for Prospective Patient Selection in Two Phase II Registration Studies of Osimertinib
|
Shepherd F.A.;Cantarini M;Patel S;Dearden S;Weston S;Hodge R;Yu K;Thress K.S;J?nne P.A;Chih-Hsin Yang;Jenkins S; Jenkins S; Chih-Hsin CHIH-HSIN YANG; Jänne P.A; Thress K.S; Yu K; Hodge R; Weston S; Dearden S; Patel S; Cantarini M; Shepherd F.A. |
| 臺大學術典藏 |
2020-05-26T09:26:37Z |
EGFR Mutation Analysis for Prospective Patient Selection in Two Phase II Registration Studies of Osimertinib
|
Shepherd F.A.;Cantarini M;Patel S;Dearden S;Weston S;Hodge R;Yu K;Thress K.S;J?nne P.A;Chih-Hsin Yang;Jenkins S; Jenkins S; Chih-Hsin CHIH-HSIN YANG; Jänne P.A; Thress K.S; Yu K; Hodge R; Weston S; Dearden S; Patel S; Cantarini M; Shepherd F.A. |
| 臺大學術典藏 |
2020-05-26T09:26:35Z |
Modulation of Biomarker Expression by Osimertinib: Results of the Paired Tumor Biopsy Cohorts of the AURA Phase I Trial
|
Thress K.S;Jacobs V;Angell H.K;Chih-Hsin Yang;Sequist L.V;Blackhall F;Su W.-C;Schuler M;Wolf J;Gold K.A;Cantarini M;Barrett J.C;J?nne P.A.; Thress K.S; Jacobs V; Angell H.K; CHIH-HSIN YANG; Sequist L.V; Blackhall F; Su W.-C; Schuler M; Wolf J; Gold K.A; Cantarini M; Barrett J.C; Jänne P.A. |
| 臺大學術典藏 |
2020-05-26T09:26:35Z |
Modulation of Biomarker Expression by Osimertinib: Results of the Paired Tumor Biopsy Cohorts of the AURA Phase I Trial
|
Thress K.S;Jacobs V;Angell H.K;Chih-Hsin Yang;Sequist L.V;Blackhall F;Su W.-C;Schuler M;Wolf J;Gold K.A;Cantarini M;Barrett J.C;J?nne P.A.; Thress K.S; Jacobs V; Angell H.K; CHIH-HSIN YANG; Sequist L.V; Blackhall F; Su W.-C; Schuler M; Wolf J; Gold K.A; Cantarini M; Barrett J.C; Jänne P.A. |
| 臺大學術典藏 |
2020-05-26T09:26:31Z |
CNS response to osimertinib in patients with T790M-positive advanced NSCLC: Pooled data from two phase II trials
|
Jänne P.A; CHIH-HSIN YANG; Mitsudomi T; Johnson M; Cantarini M; Chih-Hsin Yang;J?nne P.A;Mitsudomi T;Johnson M;Cantarini M;Hodge R;Morabito A;Felip E;De Marinis F;Crin? L;Bazhenova L;Ahn M.-J;Shepherd F.A;Tsai C.-M;Goss G; Goss G; Tsai C.-M; Shepherd F.A; Ahn M.-J; Bazhenova L; Crinò L; de Marinis F; Felip E; Morabito A; Hodge R |
| 臺大學術典藏 |
2020-05-26T09:26:31Z |
CNS response to osimertinib in patients with T790M-positive advanced NSCLC: Pooled data from two phase II trials
|
Jänne P.A; CHIH-HSIN YANG; Mitsudomi T; Johnson M; Cantarini M; Chih-Hsin Yang;J?nne P.A;Mitsudomi T;Johnson M;Cantarini M;Hodge R;Morabito A;Felip E;De Marinis F;Crin? L;Bazhenova L;Ahn M.-J;Shepherd F.A;Tsai C.-M;Goss G; Goss G; Tsai C.-M; Shepherd F.A; Ahn M.-J; Bazhenova L; Crinò L; de Marinis F; Felip E; Morabito A; Hodge R |
| 臺大學術典藏 |
2020-05-26T09:26:22Z |
Osimertinib in patients with T790M mutation-positive, advanced non?�small cell lung cancer: Long-term follow-up from a pooled analysis of 2 phase 2 studies
|
Ahn M.-J;Tsai C.-M;Shepherd F.A;Bazhenova L;Sequist L.V;Hida T;Chih-Hsin Yang;Ramalingam S.S;Mitsudomi T;Jnne P.A;Mann H;Cantarini M;Goss G.; Ahn M.-J; Tsai C.-M; Shepherd F.A; Bazhenova L; Sequist L.V; Hida T; CHIH-HSIN YANG; Ramalingam S.S; Mitsudomi T; Jnne P.A; Mann H; Cantarini M; Goss G. |
| 臺大學術典藏 |
2020-05-26T09:26:22Z |
Osimertinib in patients with T790M mutation-positive, advanced non?�small cell lung cancer: Long-term follow-up from a pooled analysis of 2 phase 2 studies
|
Ahn M.-J;Tsai C.-M;Shepherd F.A;Bazhenova L;Sequist L.V;Hida T;Chih-Hsin Yang;Ramalingam S.S;Mitsudomi T;Jnne P.A;Mann H;Cantarini M;Goss G.; Ahn M.-J; Tsai C.-M; Shepherd F.A; Bazhenova L; Sequist L.V; Hida T; CHIH-HSIN YANG; Ramalingam S.S; Mitsudomi T; Jnne P.A; Mann H; Cantarini M; Goss G. |
| 國立成功大學 |
2020 |
Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study
|
Sequist, L.V.;Han, J.-Y.;Ahn, M.-J.;Cho, B.C.;Yu, H.;Kim, S.-W.;Yang, J.C.-H.;Lee, J.S.;Su, W.-C.;Kowalski, D.;Orlov, S.;Cantarini, M.;Verheijen, R.B.;Mellemgaard, A.;Ottesen, L.;Frewer, P.;Ou, X.;Oxnard, G. |
| 臺大學術典藏 |
2017 |
Osimertinib in pretreated T790M-positive advanced non-small-cell lung cancer: AURA study phase II extension component
|
J?nne P.A.;Ghiorghiu S;Cantarini M;Mann H;Chia-Chi Lin;Hirashima T;Gold K;Novello S;Yoh K;Haggstrom D;Blackhall F;Felip E;Planchard D;Kim J.-H;Kim S.-W;Su W.-C;Sequist L.V;Ramalingam S.S;Kim D.-W;Ahn M.-J;Yang J.C.-H; Yang J.C.-H; Ahn M.-J; Kim D.-W; Ramalingam S.S; Sequist L.V; Su W.-C; Kim S.-W; Kim J.-H; Planchard D; Felip E; Blackhall F; Haggstrom D; Yoh K; Novello S; Gold K; Hirashima T; Chia-Chi Lin; Mann H; Cantarini M; Ghiorghiu S; J?nne P.A. |
| 臺大學術典藏 |
2017 |
Osimertinib in pretreated T790M-positive advanced non-small-cell lung cancer: AURA study phase II extension component
|
J?nne P.A.;Ghiorghiu S;Cantarini M;Mann H;Chia-Chi Lin;Hirashima T;Gold K;Novello S;Yoh K;Haggstrom D;Blackhall F;Felip E;Planchard D;Kim J.-H;Kim S.-W;Su W.-C;Sequist L.V;Ramalingam S.S;Kim D.-W;Ahn M.-J;Yang J.C.-H; Yang J.C.-H; Ahn M.-J; Kim D.-W; Ramalingam S.S; Sequist L.V; Su W.-C; Kim S.-W; Kim J.-H; Planchard D; Felip E; Blackhall F; Haggstrom D; Yoh K; Novello S; Gold K; Hirashima T; Chia-Chi Lin; Mann H; Cantarini M; Ghiorghiu S; J?nne P.A. |
| 國立成功大學 |
2017 |
Modulation of Biomarker Expression by Osimertinib: Results of the Paired Tumor Biopsy Cohorts of the AURA Phase I Trial
|
Thress, K.S.;Jacobs, V.;Angell, H.K.;Yang, J.C.-H.;Sequist, L.V.;Blackhall, F.;Su, W.-C.;Schuler, M.;Wolf, J.;Gold, K.A.;Cantarini, M.;Barrett, J.C.;J�nne, P.A. |
